Evaluation of Enhanced Condensational Growth (ECG) for Controlled Respiratory Drug Delivery in a Mouth-Throat and Upper Tracheobronchial Model
- 244 Downloads
The objective of this study is to evaluate the effects of enhanced condensational growth (ECG), as a novel inhalation drug delivery method, on nano-aerosol deposition in a mouth-throat (MT) and upper tracheobronchial (TB) model using in vitro experiments and computational fluid dynamics (CFD) simulations.
Separate streams of nebulized nano-aerosols and saturated humidified air (39°C—ECG; 25°C—control) were combined as they were introduced into a realistic MT-TB geometry. Aerosol deposition was determined in the MT, generations G0-G2 (trachea—lobar bronchi) and G3-G5 and compared to CFD simulations.
Using ECG conditions, deposition of 560 and 900 nm aerosols was low in the MT region of the MT-TB model. Aerosol drug deposition in the G0-G2 and G3-G5 regions increased due to enhanced condensational growth compared to control. CFD-predicted depositions were generally in good agreement with the experimental values.
The ECG platform appears to offer an effective method of delivering nano-aerosols through the extrathoracic region, with minimal deposition, to the tracheobronchial airways and beyond. Aerosol deposition is then facilitated as enhanced condensational growth increases particle size. Future studies will investigate the effects of physio-chemical drug properties and realistic inhalation profiles on ECG growth characteristics.
KEY WORDScomputational fluid dynamics condensational growth in vitro aerosol deposition nano-aerosol drug delivery respiratory drug delivery
computational fluid dynamics
dry powder inhaler
enhanced condensational growth
metered dose inhaler
This study was supported by Award Number R21HL094991 from the National Heart, Lung, And Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health.
- 6.Longest PW, Hindle M, Das Choudhuri S, Byron PR. Developing a better understanding of spray system design using a combination of CFD modeling and experiment. In: Dalby RN et al., editors. Proceedings of Respiratory Drug Delivery 2008. Illinois: Davis Healthcare International; 2008. p. 151–63.Google Scholar
- 7.Hindle, M. Soft mist inhalers: a review of current technology. The Drug Delivery Companies Report Autumn/Winter. 2004;31–4.Google Scholar
- 26.Martonen TB, Bell KA, Phalen RF, Wilson AF, Ho A. Growth rate measurements and deposition modeling of hygroscopic aerosols in human tracheobronchial models. In: Walton WH, editor. Inhaled particles V. Oxford: Pergamon; 1982. p. 93–107.Google Scholar
- 28.Longest PW, Hindle M, Xi J. Effective delivery of nanoparticles and micrometer-sized pharmaceutical aerosols to the lung through enhanced condensational growth. International Patent Application PCT/US2009/034360: 2009.Google Scholar
- 29.Hinds WC. Aerosol technology: properties, behavior, and measurement of airborne particles. New York: Wiley; 1999.Google Scholar
- 31.Longest PW, Hindle M. CFD simulations of enhanced condensational growth (ECG) applied to respiratory drug delivery with comparisons to in vitro data. J Aerosol Sci. 2010. doi: 10.1016/j.jaerosci.2010.04.006.
- 36.Longest PW, Hindle M. Evaluation of the respimat soft mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med. 2009;22:99–112.Google Scholar
- 37.Longest PW, Hindle M, Das Choudhuri S. Effects of generation time on spray aerosol transport and deposition in models of the mouth-throat geometry. J Aerosol Med. 2009;22:67–84.Google Scholar
- 44.Byron PR, Delvadia RR, Longest PW, Hindle M. Stepping into the Trachea with Realistic Physical Models: Uncertainties in Regional Drug Deposition from Powder Inhalers. In: Dalby, RN et al.,editors. Respiratory Drug Delivery 2010. Illinois: Davis Healthcare International Publishing; 2010. (in press).Google Scholar